|
Tracleer and PPH News
Girl makes progress in battle with rare primary pulmonary hypertension, or PPH
PPH is characterized by high blood pressure in the pulmonary artery due to unexplained changes in the small blood vessels in the lungs, which impedes blood flow through the vessels. This can cause enlargement and subsequent failure of the heart.
Accredo Health Signs Exclusive Five-year Specialty Pharmacy Agreement for Flolan
Under the agreement, Accredo will provide specialty pharmacy management and prescription fulfillment service through its network of 32 pharmacies, each with dedicated PAH pharmacists and nurses, National Distribution Center, and National Customer Support Center.
Myogen Initiates Phase 3 Clinical Trial of Darusentan in Patients with Resistant Hypertension
The primary objective of DORADO, a Phase 3 randomized, double-blind, placebo-controlled parallel group trial, is to determine if darusentan is effective in reducing systolic blood pressure in resistant hypertension patients currently treated with full doses of four or more antihypertensive medications, one of which is a diuretic.
Drugs in Development - Endothelin Receptor Antagonist
Ambrisentan is being developed as a once-daily oral therapy for patients with pulmonary arterial hypertension and has been granted orphan-drug designation in the United States and European Union.
Painkillers Raise Heart Attack Risk
Painkillers called COX-2 inhibitors may increase the risk of heart attacks by raising blood pressure and making the blood more likely to clot, researchers said on Thursday.
PPH and Lung Transplantation in the U.S.
Primary pulmonary hypertension is caused by a progressive narrowing of the blood vessels in the lungs, leading to high blood pressure in the affected vessels. Patients may experience shortness of breath, fatigue, dizziness, weakness, fainting, chest pain, swelling of the ankles and a bluish coloring of the lips and skin. Eventually, heart failure occurs.
PAH Market Ripe For Expansion As Big Pharma Interest Increases
Off-label anti-coagulants, diuretics, and calcium-channel blockers are often used to treat pulmonary arterial hypertension (PAH), with more targeted therapies like endothelin receptor antagonists, phosphodiesterase-5 inhibitors and prostacyclins also used extensively. While these treatments have all shown considerable efficacy, their shortcomings leave considerable unmet need in the PAH market.
Sildenafil Citrate Drug Gives Girl New Hope
Rodriguez has taken liquid sildenafil citrate-the active ingredient in the erectile dysfunction drug Viagra-for a few months to treat secondary pulmonary hypertension, a lung condition caused by a heart defect.
Resident with rare disease aims to educate, help others
Bohn is currently on Epoprostenol (or Flolan) which helps to open up her constricted lung blood vessels, and reduces high blood pressure in her lungs. It is delivered by a constant intravenous infusion
Pulmonary Arterial Hypertension Positive Results for Ambrisentan Phase 3 Trial
Myogen, Inc. (Nasdaq: MYOG) today announced positive top line results of the ARIES-2 trial, the first pivotal Phase 3 trial evaluating ambrisentan, an oral endothelin receptor antagonist (ERA), in pulmonary arterial hypertension (PAH).
Positive Results from Trust Study of Intravenous Remodulin
United Therapeutics Corporation announced today the preliminary results of its 45-patient placebo-controlled TRUST trial are positive, (p=0.00767). Specifically, intravenous Remodulin produced an 83-meter median improvement in six-minute walk distance compared to placebo after twelve weeks in patients with NYHA Class III/IV pulmonary arterial hypertension.
PR Pharmaceuticals Files IND for Pulmonary Hypertension
PR Pharmaceuticals, Inc. (PRP), announced today that it filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for the Company's first clinical product, PulmoLAR(TM) (2-methoxyestradiol) for the treatment of pulmonary arterial hypertension (PAH).
Tasmar, Amplimexon, IV Remodulin Gain International Approvals
The Drug Registration Department of Israel's Ministry of Health approved a new route of administration for treprostinil sodium injection (Remodulin, made by United Therapeutics Corporation and distributed by Pharmateam Marketing), allowing its use as an intravenous infusion for the treatment of primary pulmonary arterial hypertension.
FDA Approves Expanded Label and Accelerated Approval for Remodulin (Treprostinil Sodium) Injection
The Phase 4 study, which was successfully completed last year, involved the transition of patients from Flolan to either Remodulin or placebo. In the trial, 13 of 14 patients (93%) randomized to Remodulin were able to successfully transition from Flolan and complete the study without the need to re-institute Flolan therapy
The Effect of Tracleer·on Male Fertility
The objective of the study is to evaluate the effects of chronic TRACLEER treatment on testicular function via semen analysis in male patients with primary pulmonary arterial hypertension (PPH).
Actelion Tracleer drug fails to help lung-disease
Tracleer, currently Actelion's leading product, accounting for virtually all of its sales, failed to show any effect in the primary endpoint of clinical trials on patients with two forms of pulmonary fibrosis. While not helping in exercising, the drug did, however, show positive trends in secondary measures related to death and disease worsening.
Pharma Reformulates
A class encompassing other hormones was boosted by the arrival of Lilly's Forteo, an injectable recombinant human parathyroid hormone for osteoporosis, while a class of “other cardiovascular” products gained through Actelion's pulmonary hypertension therapy Tracleer.
Rare Pulmonary Hypertension Condition Affects Girls Lives
Pulmonary Hypertension, or PH, means there is continuous high blood pressure in the pulmonary artery of the lungs. Eventually this can result in an enlarged heart, which could loose its ability to pump.
Myogen Riding High After Preliminary PAH Findings
The trial showed that the small molecule bettered patients' exercise capacity, the primary efficacy endpoint, improved a key secondary endpoint of time to clinical worsening and several other secondary efficacy endpoints.
New Portable Inhalation Device to Ventavis Patients From CoTherix and Respironics
CoTherix, Inc. and Respironics, Inc. announced today the launch of a new portable, battery-operated inhalation device for the delivery of Ventavis® (iloprost) Inhalation Solution. The new I-neb(TM) Adaptive Aerosol Delivery® (AAD) device weighs less than eight ounces and can be carried discreetly in a purse, pocket or briefcase. Ventavis is indicated for the treatment of pulmonary arterial hypertension (PAH).
Tracleer Study First Ever to Show Benefits in Eisenmenger's Syndrome
Actelion Ltd (SWX:ATLN) (Other OTC:ALIOF) announced today that in the BREATHE-5 study evaluating the use of Tracleer(r) (bosentan) in pulmonary arterial hypertension (PAH) related to Eisenmenger's syndrome, patients significantly increased their exercise capacity and decreased pulmonary vascular resistance (PVR) under treatment
Penn Study Points to New Evidence to Explain How COX-2 Inhibitors Can Eventually Lead to Heart Disease and Stroke
University of Pennsylvania School of Medicine researchers have found additional evidence that may help explain how selective inhibitors of COX-2 might predispose individuals to heart disease and stroke. In Circulation Research, they report that a COX-2-derived fatty substance -- a prostaglandin called prostacyclin -- controls the blood-vessel response to stresses such as high-blood pressure, thereby further linking COX-2 inhibitors to an increased risk of heart attack or stroke.
Ventavis Scrutinized for IPF-Related Pulmonary Hypertension
A medication already approved as a therapy for people with pulmonary hypertension (PH) is about to enter a second round of clinical testing to determine if it's safe for those with PH related to another lung disease known as idiopathic pulmonary fibrosis, or IPF
Viagra treats kids' deadly lung condition
PAH is a condition in which blood pressure in the arteries that supply the lungs is extremely high. If the pressure soars high enough, the heart can't keep up, causing fatigue, dizziness, shortness of breath and eventually heart failure and death.
Bill would fund research for PHT treatment
The Pulmonary Hypertension Research Act, co-sponsored by Reps. Kevin Brady, R-Texas, and Tom Lantos, D-Calif., may give hope to people like John Kostur, a 42-year-old Maryland resident who suffers from PHT and must wear a device the size of a cassette-tape player that continuously pumps a drug called Flolan into his bloodstream.
Dark chocolate seen healthy for arteries
Eating dark chocolate may have a protective effect on the cardiovascular system in healthy people, the results of a new study suggest. The researchers examined the effects of flavonoid-rich dark chocolate on blood-vessel function in 17 young, healthy volunteers over a 3-hour period after they consumed 100 grams of a commercially available dark chocolate.
Encysive to Retain European Rights to Thelin
Thelin is a small molecule that blocks the action of endothelin, a potent mediator of blood vessel constriction and growth of smooth muscle in vascular walls. Endothelin receptor antagonists may prove to be effective in the treatment of a variety of diseases where the regulation of vascular constriction is important.
Viagra helps childhood lung condition - pulmonary arterial hypertension
The impotence drug Viagra, originally developed to treat heart disease, may help children with a serious heart-lung condition to walk further and breathe more easily, researchers said on Monday.
FDA Clears Way for New Pulmonary Hypertension Drug
People with pulmonary hypertension now have a new treatment option at their disposal. The U.S. Food and Drug Administration has approved the drug Revatio, known by its generic name sildenafil citrate, for pulmonary arterial hypertension, says its manufacturer, Pfizer.
Basket bingo to benefit two Scout leaders with illnesses
As were her family members before her, Peck has been diagnosed with primary pulmonary hypertension - a rare lung disorder in which the blood pressure in the pulmonary artery rises far above normal levels for no apparent reason.
Abstracts at European Congress of Rheumatology (EULAR) Highlight Positive Long-term Impact of Tracleer (bosentan) in the Treatment of PAH Associated with Systemic Sclerosis
Actelion Ltd (SWX: ATLN) announced today that abstracts presented today at the Annual European Congress of Rheumatology - organized by the European League Against Rheumatism (EULAR) - show the positive impact of Tracleer® (bosentan) in treating pulmonary arterial hypertension (PAH) in patients with systemic sclerosis (scleroderma)1,2.
FDA Clears Way for New PH Drug
People with pulmonary hypertension now have a new treatment option at their disposal. The U.S. Food and Drug Administration has approved the drug Revatio, known by its generic name sildenafil citrate, for pulmonary arterial hypertension, says its manufacturer, Pfizer.
New use for Viagra: Treating lung disease
Viagra, the erectile-dysfunction drug used by more than 26 million men worldwide, was reborn Monday as Revatio, a drug to treat pulmonary hypertension, a rare, fatal lung disease caused by constrictions in the blood vessels that supply the lungs.
Long-Term Response Achieved With Inhaled Prostacyclin for PAH
The 39 patients with primary idiopathic pulmonary hypertension had a two-year survival rate of 91% compared with a predicted survival of 63% for an untreated historical cohort based on the National Institutes of Health registry, Dr. Olschewki said.
FDA Accused of Dropping the Ball on Post-Marketing Studies of Fast Track Drugs
He lists 16 drugs that are awaiting confirmatory post-marketing studies: Alimta, Arimidex, Celebrex, Depocyt, Ethyol, Gleevec, Iressa, Luveris, Mylotarg, Proamatine, Remodulin, Sulfamylon, Synercid, Truvada, Velcade and Viread.
CoTherix Initiates Phase II Trial for Ventavis in Expanded Indication
Idiopathic pulmonary fibrosis (IPF) is a progressive and potentially fatal disease that results in fibrosis, or scarring, of the lungs. In time, fibrosis can accumulate until the lungs are unable to provide oxygen for the tissues of the body. The average survival rate for patients is four to six years after diagnosis.
Thelin: Docs Release More Findings in Thelin PH Drug Trial
The trial, lasting 18 weeks, put the drug Thelin, also known by its generic name sitaxsentan, to the test in a group of 246 patients with the disease. A group in the study also received the already approved PH drug, Tracleer (bosentan), to compare the results.
Encysive Submits Thelin NDA In PAH, Seeks Accelerated Review
Another differentiating factor between Thelin and Tracleer is the latter's interaction with sildenafil (Viagra, from Pfizer Inc.), a PDE5 inhibitor that increasingly is seeing use off label as another component in treating PAH.
Actelion Ltd: Long-Term Tracleer (bosentan) Safety Profile Confirmed with Completion of Non-Interventional Program in Almost 5,000 Patients
PAH is a devastating disease. Untreated, PAH patients die an average of 2.8 years after diagnosis. Tracleer(R) (bosentan) is the first and only approved oral treatment for PAH (Class III and IV) to improve exercise capacity and decrease the time to clinical worsening. Bosentan is a dual endothelin receptor antagonist (ERA). Encysive Announces Six Thelin(TM) Abstracts Presented at American Thoracic Society International Conference
The five PAH drugs for which both placebo and non-placebo controlled 6MW data were available included: Thelin (sitaxsentan), Tracleer® (bosentan), Ventavis® (iloprost), Remodulin® (treprostinil) and beraprost. Myogen Initiates Trial of Ambrisentan in Patients Who Previously Failed Other ERA Therapy
The primary objective of this trial is to determine the incidence of increased serum aminotransferase concentrations associated with ambrisentan therapy in patients who have previously discontinued bosentan or sitaxsentan therapy due to serum aminotransferase abnormalities. Predix Pharmaceuticals Initiates Phase I Clinical Trial of 5-HT2B Receptor Antagonist for Pulmonary Hypertension
As a selective 5-HT2B antagonist, PRX-008066 has the potential to act both as a vasodilator of pulmonary but not systemic blood vessels, and as a disease-modifying agent to slow the progression of the disease. Enrollment Completed in Phase 2b Trial of Darusentan in Patients With Resistant Systolic Hypertension
Hypertension affects approximately 50 million individuals in the United States and approximately one billion worldwide. Despite the availability and use of several classes of drugs (diuretics, ACE inhibitors, angiotensin receptor blockers, beta-blockers, calcium channel blockers, central alpha receptor agonists, peripheral antagonists and vasodilators) to treat hypertension New Thelin Data to be Presented at American Thoracic Society's International Conference
Pulmonary arterial hypertension (PAH) is a condition that involves high blood pressure and structural changes in the walls of the pulmonary arteries, which are the blood vessels that connect the right side of the heart to the lungs. Medtronic Announces Expanded Labeling for Its Model 407C General Medication Pump
The external pump can deliver medications to treat a variety of medical conditions including, but not limited to, cancer and pain. Currently, Medtronic's general medication pump is being used to deliver Remodulin(R), manufactured by United Therapeutics Corporation (NASDAQ:UTHR), for the treatment of pulmonary arterial hypertension.
International Approvals: Follistim, Tracleer, Prograf
On April 11, the Japanese Ministry of Health, Labor, and Welfare approved bosentan tablets (Tracleer, made by Actelion, Ltd) for the treatment of all forms of pulmonary arterial hypertension (PAH) in patients with World Health Organization class III or IV symptoms to improve exercise ability and decrease the rate of clinical worsening.
FDA Approves Pfizer's Revatio As Treatment for Pulmonary Arterial Hypertension
Pfizer Inc said today the U.S. Food and Drug Administration has approved Revatio(TM) (sildenafil citrate) as a treatment for pulmonary arterial hypertension (PAH), a rare, aggressive and life-shortening vascular disease. Sildenafil citrate is the active ingredient in Viagra®, Pfizer's erectile dysfunction medication used by more than 26 million men worldwide.
Actelion Ltd: Japanese Approval for Tracleer in PAH
Actelion Ltd announced today that the Japanese Ministry of Health, Labor and Welfare has granted formal approval for Tracleer (bosentan) in Pulmonary Arterial Hypertension (PAH). Tracleer has been approved for patients suffering from all forms of PAH
International Approvals: Ceplene, Reducol, Remodulin
French regulatory authority (Agence Française de Sécurité Sanitaire des Produits de Santé) approved treprostinil sodium injection (Remodulin, made by United Therapeutics Corp.) for subcutaneous administration in the treatment of primary pulmonary arterial hypertension (PAH) A Drug to Get Your Blood Pumping
One approved drug is Tracleer, from Swiss company Actelion. Tracleer has been commercially successful, with sales of several hundred million dollars a year.
Encysive Drug Study Comes To An End
A 50 mg dose of Thelin improved 6MW by 24.2 meters, and bosentan (Tracleer), currently the only approved oral agent for treating PAH, improved 6MW by 29.5 meters. Wait is over: Woman gets heart, lungs
Vulhop had a complex congenital heart defect known as double outlet right ventricle, and developed severe pulmonary hypertension and congestive heart failure. New PH Therapy Gets FDA Nod
Current therapy includes a range of medications to alleviate constricted pulmonary vessels like calcium channel blockers, epoprostenol (Flolan), Remodulin (treprostinil), and warfarin (Coumadin). Taking liver-taxing drugs calls for periodic testing
Following is a representative list of drugs that call for liver function monitoring to help ensure safe use: Acarbose (Precose), amiodarone (Cordarone), amprenavir (Agenerase), atorvastatin (Lipitor), azathioprine (Imuran), bosentan (Tracleer), carbamazepine (Tegretol), celecoxib (Celebrex)... CoTherix's Ventavis(R) Commercially Available for the Treatment of Pulmonary Arterial Hypertension
Based on the positive results from our STEP trial evaluating the combination of Ventavis added to Tracleer therapy, we believe there is an opportunity for Ventavis to be used early in the course of the disease Renin Alliance of Actelion and Merck & Co., Inc. Achieves Second Milestone
Actelion and Merck formed an exclusive worldwide alliance in December 2003 to discover, develop and market new classes of renin inhibitors for patients suffering from cardio-renal diseases. CoTherix Reports Positive Clinical Data From STEP Study
The analysis of this study showed that the combination of Ventavis® (iloprost) Inhalation Solution added to Tracleer® (bosentan) therapy was well tolerated and provided clinical benefit in patients with pulmonary arterial hypertension (PAH). Speedel Brings In CHF47.8M To Advance Pipeline Projects
SPP200, a recombinant human protein undergoing a Phase II trial for an undisclosed cardiovascular indication, remains under Speedel's control, but an undisclosed U.S. pharmaceutical firm, which originally discovered the compound, retains a callback option. Long-Term Survival Using Tracleer for PH Faces Scrutiny
A new, oral medication approved as a therapy for primary pulmonary hypertension (PH) was tested recently in a large study, and the physicians who participated concluded the drug improved survival for patients as compared to the odds they might have faced with no treatment Actelion Provides Update on Bosentan in Japan
Tracleer(r), the first oral dual endothelin receptor antagonist, is approved for the treatment of pulmonary arterial hypertension (PAH) and made available by Actelion subsidiaries in the United States, the European Union, Australia, Canada, Switzerland, Israel, Hong Kong, Malaysia, Singapore and Brazil as well as several other smaller territories worldwide. The Critically Ill Patient With Pulmonary Hypertension
Pulmonary hypertension (PH) is a common problem in the intensive care unit (ICU). PH can arise in critically ill patients as a consequence of acute respiratory distress syndrome, as a result of the mode of mechanical ventilation (MV) used, or as complication of the patient's underlying disease (eg, emphysema). Encysive Drug Thelin Meets Study Endpoint
Compared with Actelion's Tracleer, currently the only approved oral treatment for pulmonary arterial hypertension, a 50 mg dose of Thelin improved the walk by 24.2 meters, and Tracleer improved the walk by 29.5 meters. FDA Safety Labeling Changes: Depo-Provera, Tracleer, Tabloid
FDA approved revisions to the safety labeling for bosentan (Tracleer tablets, made by Actelion, Inc.), warning that concurrent use of transdermal hormonal contraceptives (in addition to oral, injectable, and implantable formulations) may decrease the contraceptives' efficacy and that they should not be relied on as a sole means of contraception. Actelion Ltd -- Scientific Publication on Long-Term Bosentan Use in PPH
A total of 245 patients with PAH were enrolled in the two placebo-controlled trials. At the end of these studies, all patients were offered bosentan therapy. The results published today are from the long-term follow-up of the 169 patients with primary pulmonary hypertension (PPH). Long-term treatment with bosentan improves outcomes in pulmonary arterial hypertension, European Respiratory Journal
Bosentan, a dual endothelin receptor antagonist, is the first approved oral treatment for PAH. In short-term (12-16 week) trials, bosentan has demonstrated improvements in how far patients can walk and how they feel. Long-Term Survival Using Tracleer for PPH Faces Scrutiny
A new, oral medication Tracleer approved as a therapy for primary pulmonary hypertension (PPH) was tested recently in a large study, and the physicians who participated concluded the Tracleer drug improved survival for PPH patients as compared to the odds with no treatment. Scientific Publication on Long-Term Bosentan Use in PPH
Actelion Ltd (Other OTC:ALIOF) (SWX:ATLN) announced today the publication of the scientific paper evaluating disease outcome of patients with advanced primary pulmonary arterial hypertension receiving Tracleer(r) (bosentan). 3 Fen-Phen victims win $500,000
This was the 10th fen-phen case to be tried in the same Philadelphia court since July. Wyeth has set aside more than $16 billion to resolve cases involving the Fen-Phen mixture, which included the company's Pondimin or Redux and generic phentermine. Public 'Defenseless' Vs. Bad Drugs
Graham told the committee that research indicated that Vioxx caused up to 160,000 heart attacks and strokes. He said his research helped persuade the FDA to withdraw a number of drugs, including Fen-phen, a weight loss drug. Acomplia diet drug shows real promise
In early clinical trials, Acomplia is looking promising. But with only 3,000+ people tested so far, it's far from being approved by the FDA. And even as effective as Acomplia appears to be in early tests, much of the hype is overblown Wyeth Backs Changes to Diet Drug Settlement
Wyeth said it is endorsing the proposed changes after their approval by an overwhelming majority of former users of its two drugs, Pondimin and Redux. The drugs were recalled in 1997 after being linked to heart valve damage and a highly fatal lung condition. FDA Approves Breakthrough Therapies
The FDA in 2004 approved 32 new therapeutic products discovered, developed or marketed by biotechnology and related companies, according to a BIO analysis FDA Approves Ventavis(TM) for the Treatment of Pulmonary Arterial Hypertension (PAH)
CoTherix, Inc. today announced that following priority review, the U.S. Food and Drug Administration (FDA) has approved Ventavis(TM) (iloprost) Inhalation Solution for the treatment of pulmonary arterial hypertension (PAH) in patients with NYHA Class III or IV symptoms FDA Approvals: Ventavis, Kepivance, Captique
The U.S. Food and Drug Administration (FDA) has approved iloprost inhalation solution for the treatment of severe pulmonary arterial hypertension Viagra helps boy with lung disease
"They told us we could try him on either Flolan, which is an IV drug. He would have to wear a pack continuously... Or they could try a new drug, which was the Viagra," said Jennifer Gendron. New Treatment, Significant Improvement for HIV-related Heart Condition
Treatment with the oral drug bosentan (Tracleer) led to significant improvements in an often fatal disease, pulmonary arterial hypertension, according to a new study. PAH is usually linked with human immunodeficiency virus infection.
Patients call for an end to red tape
About 30 patients who suffer from a rare lung disease known as pulmonary arterial hypertension (PAH) yesterday called on the government to relax regulations on life-saving drugs and give them the costly medication before the disease catches up with them. Actelion Initiates Phase IIb/III Program With Clazosentan
Actelion Ltd announced today it has initiated the comprehensive global Phase IIb/III development program for clazosentan, an intravenous endothelin receptor antagonist. Scientific Publication of RAPIDS-1 Study with Bosentan
Tracleer(r), the first orally available dual endothelin receptor antagonist for the treatment of pulmonary arterial hypertension (PAH), a chronic life-threatening condition that severely compromises the function of the lungs and heart is already approved in the US CoTherix Gets Approval For Inhaled PAH Drug Ventavis
Providing a new, less-invasive treatment option for pulmonary arterial hypertension patients, CoTherix Inc. received FDA approval for Ventavis, an inhaled product in-licensed from Schering AG in October 2003. TRACLEER WILL NOT EXPAND INTO TREATMENT OF CONGESTIVE HEART FAILURE
In late November, the FDA approved Tracleer for the treatment of PAH. The drug is indicated to improve exercise ability and decrease the rate of clinical worsening in PAH patients with significant limitation of physical activity. Tracleer is the first approved oral treatment for PAH patients. Lung disease drug Tracleer 'a revolution'
Tracleer today became the first drug listed on the Pharmaceutical Benefits Scheme to help control the lung disease pulmonary arterial hypertension (PAH). The disease mostly affects women aged 20 to 45, but also occurs in young children and adult men. Successful study with Tracleer® (bosentan) in scleroderma patients
Tracleer®, the first orally available dual endothelin receptor antagonist for the treatment of pulmonary arterial hypertension (PAH), a chronic life-threatening condition that severely compromises the function of the lungs and heart is already approved in the US New scientific studies show higher than expected prevalence of Pulmonary Arterial Hypertension in patients with Connective Tissue Diseases (CTD)
Two scientific studies at the American College of Rheumatology report a high prevalence of diagnosed and undiagnosed pulmonary arterial hypertension (PAH) in patients with scleroderma and mixed connective tissue disease (MCTD) Bosentan in metastatic melanoma well tolerated at high doses
All these trials involving the orally available dual endothelin antagonist bosentan (Tracleer®), currently approved for the treatment of Pulmonary Arterial Hypertension (PAH), are now recruiting as scheduled. Actelion reports further progress to additional markets for Tracleer in Pulmonary Arterial Hypertension
Around 100,000 people in Europe and the US currently suffer from pulmonary arterial hypertension, which includes PPH or PAH related to other diseases such as scleroderma, a degenerative connective tissue disease. Results of Treatment with Oral Tracleer (bosentan)
Actelion Ltd (SWX: ATLN) today announced results of a study assessing its oral dual endothelin receptor antagonist (ERA) Tracleer® (bosentan) in the treatment of pulmonary arterial hypertension (PAH) related to HIV (human immunodeficiency virus) infection. Analysis suggests Tracleer® (bosentan) improved survival in primary pulmonary hypertension patients
Actelion announced the analysis of long-term follow-up data of primary pulmonary hypertension patients from Tracleer® pivotal registration studies that suggests the oral dual endothelin receptor antagonist is associated with improved survival.
| 
